- Home
- GPGI vs RCUS Comparison
GPGI vs RCUS Comparison
Compare GPGI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$17.98
Company Overview
Basic Information| Metric | GPGI | RCUS |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GPGI | RCUS |
|---|---|---|
| Price | $13.02 | $17.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $20.00 | ★ $41.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.4M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $59,824,000.00 | ★ $247,000,000.00 |
| Revenue This Year | $3,276.36 | N/A |
| Revenue Next Year | $15.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.43 | $17.43 |
| 52 Week High | $25.66 | $31.74 |
Technical Indicators
Market Signals| Indicator | GPGI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 39.14 |
| Support Level | $12.54 | $17.97 |
| Resistance Level | $13.12 | $24.46 |
| Average True Range (ATR) | 0.72 | 1.59 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 86.72 | 25.86 |
Price Performance
Historical Comparison GPGI
RCUS
About GPGI GPGI Inc.
GPGI Inc is a diversified holding permanent capital platform designed to acquire, own, and scale high-quality businesses that hold great positions in good industries.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.